| Chelation therapy does not reduce the occurrence of major adverse cardiovascular events in patients with diabetes who have had a myocardial infarction even though it effectively reduces blood lead levels, according to a multicenter clinical trial funded by the National Institutes of Health (NIH). The results, which did not replicate those of an earlier trial, were published in the Journal of the American Medical Association. Chelation therapy is a process in which a substance is delivered intravenously (through the veins) to bind metals or minerals and hold them so they can be removed from the body via urination. It has been used as a complementary therapy for cardiovascular disease (CVD), although it has not been proven beneficial for this purpose. | 